Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Position Raised by BlackBarn Capital Partners LP

BlackBarn Capital Partners LP increased its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 18.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,850,000 shares of the company's stock after buying an additional 438,388 shares during the quarter. Amneal Pharmaceuticals accounts for 1.2% of BlackBarn Capital Partners LP's portfolio, making the stock its 5th largest position. BlackBarn Capital Partners LP owned about 0.92% of Amneal Pharmaceuticals worth $22,572,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $81,000. Straightline Group LLC purchased a new stake in Amneal Pharmaceuticals during the 4th quarter valued at $92,000. Cibc World Markets Corp purchased a new stake in Amneal Pharmaceuticals during the 4th quarter valued at $118,000. Janney Montgomery Scott LLC bought a new stake in Amneal Pharmaceuticals in the 4th quarter worth $121,000. Finally, Fox Run Management L.L.C. increased its position in shares of Amneal Pharmaceuticals by 69.0% in the fourth quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock valued at $162,000 after acquiring an additional 8,342 shares during the period. Hedge funds and other institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Price Performance

AMRX stock traded up $0.06 during trading on Friday, reaching $7.48. The company had a trading volume of 1,775,605 shares, compared to its average volume of 1,399,185. Amneal Pharmaceuticals, Inc. has a 52 week low of $5.81 and a 52 week high of $9.48. The business has a 50 day moving average of $8.06 and a 200 day moving average of $8.19. The company has a market cap of $2.32 billion, a P/E ratio of -11.00 and a beta of 1.06.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). The firm had revenue of $730.52 million during the quarter, compared to analysts' expectations of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same quarter in the previous year, the business earned $0.14 EPS. Research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

AMRX has been the subject of a number of analyst reports. Barclays increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $10.80.

Insider Transactions at Amneal Pharmaceuticals

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the transaction, the insider now owns 48,578,209 shares of the company's stock, valued at $405,628,045.15. This trade represents a 9.33 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the transaction, the director now owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. The trade was a 4.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,160,000 shares of company stock valued at $43,113,200 in the last three months. 17.45% of the stock is currently owned by company insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.